A BILL TO AMEND THE SOUTH CAROLINA CODE OF LAWS BY ADDING SECTION 44-6-120 SO AS TO REQUIRE THE DEPARTMENT OF HEALTH AND HUMAN SERVICES TO CONDUCT AN ANNUAL REVIEW OF MEDICATIONS AND TREATMENTS FOR CHRONIC AND RARE KIDNEY DISEASES FOR ENROLLEES IN THE SOUTH CAROLINA MEDICAID PROGRAM IN ORDER TO DETERMINE THE ADEQUACY OF THE AVAILABLE TREATMENTS AND TO MAKE RECOMMENDATIONS REGARDING POTENTIAL NEW TREATMENTS; TO REQUIRE THE DEPARTMENT TO PUBLISH AN ANNUAL REPORT; AND FOR OTHER PURPOSES.
Impact
The passage of H5486 would have significant implications on state healthcare policy by establishing a formal process for the evaluation of kidney disease treatments within the Medicaid program. This annual review process would not only aim to verify the adequacy of current treatment options but also provide a structured approach for potentially introducing new therapies that may become necessary over time. Legislators aimed to enhance the quality of care for these patients through this initiative, which could lead to improved health outcomes.
Summary
House Bill H5486 seeks to amend the South Carolina Code of Laws by introducing Section 44-6-120. This section mandates that the Department of Health and Human Services conduct an annual review of medications and treatments available under the South Carolina Medicaid program specifically aimed at individuals diagnosed with chronic and rare kidney diseases. The overarching goal of this bill is to ensure that the treatments provided to Medicaid enrollees are sufficient to meet their medical needs and to recommend any additional treatments deemed necessary.
Contention
While the bill presents a proactive measure to accommodate the healthcare needs of chronic and rare kidney disease patients, there could be points of contention regarding the allocation of Medicaid resources and the operational impact on the Department of Health and Human Services. Some may argue that increasing the scope of reviews and potential treatments adds an administrative burden, while others might highlight the necessity for such evaluations to foster patient-centered healthcare reforms. The anticipated input from the public, particularly those affected by kidney diseases, could further expose varying perspectives on the efficacy and utility of existing treatments.
A bill for an act establishing a veterans recovery pilot program and fund for the reimbursement of expenses related to providing hyperbaric oxygen treatment to eligible veterans and making appropriations.(Formerly HF 326.)
A bill for an act establishing a veterans recovery pilot program and fund for the reimbursement of expenses related to providing hyperbaric oxygen treatment to eligible veterans and making appropriations.(See HF 518.)